Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Insulin Glargine / Lixisenatide"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Diabetes, obesitymetabolism. 23(12)
AIM To compare the benefits of iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi), with insulin glargine (iGlar) for reducing residual hyperglycaemia (defined as HbA1c ≥ 7% despite fasting plasma glucose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e20032247bd5059683c93bae69e1084
https://pubmed.ncbi.nlm.nih.gov/34472693
https://pubmed.ncbi.nlm.nih.gov/34472693
Autor:
Emma D. Deeks
Publikováno v:
Drugs & Therapy Perspectives. 35:470-480
Subcutaneous insulin glargine/lixisenatide [Suliqua® 100/33 and 100/50 (EU); Soliqua® 100/33 (USA)] is a titratable, fixed-ratio combination of a long-acting basal insulin analogue + a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7637f2cf65e4dba896b11bf538617de
https://doi.org/10.1007/s40267-019-00670-4
https://doi.org/10.1007/s40267-019-00670-4
Autor:
Zubin Punthakee, Diana Sherifali, Jean-François Yale, Mohammed Azharuddin, Hertzel C. Gerstein, Ada Smith, Ronald J. Sigal, Irene Hramiak, Stewart B. Harris, Joanne Liutkus, Farah Sultan, Natalia McInnes, Yan Yun Liu, Stephanie Hall, Heather Lochnan, Rose Otto
Publikováno v:
Diabetes. 70
Background: Diabetes remission due to non-surgical approaches has not been well studied. We investigated induction of diabetes remission following a short-term treatment with insulin glargine, lixisenatide and metformin and changes in exercise and di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::340d97273fba381d12458cdc20ac268a
https://doi.org/10.2337/db21-677-p
https://doi.org/10.2337/db21-677-p
Publikováno v:
Diabetes, Obesity & Metabolism
Maintaining optimal glycaemic control reduces the risk of micro‐ and macrovascular complications in patients with type 2 diabetes. Typically, glycaemic control is based on glycated haemoglobin (HbA1c) as a measure of mean glucose concentration; how
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52b1243ea2c0e3db78b41a5d75377d41
https://doi.org/10.1111/dom.13580
https://doi.org/10.1111/dom.13580